Apremilast in Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis

In this episode, Drs. Nilasha Ghosh and Anne Bass discuss immune-related adverse events from immune checkpoint inhibitors, focusing on psoriasis and psoriatic arthritis. They review early clinical recognition, epidemiology, and findings from a multicenter observational study evaluating apremilast, including patient characteristics, outcomes, and key limitations. The conversation also highlights insights from the HSS Checkpoint Inhibitor–Associated Arthritis Registry, the need for greater precision in rheumatology, and practical perspectives on mentorship and career development for emerging clinician–scientists.  Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis